Skip to main content
  1. Life
  2. Health & Fitness
  3. Holistic Health

Armidex found to cut breast cancer risk in half for postmenopausal women

See also

A new study by researchers at Queen Mary University of London’s Center for Cancer Prevention has proven that the cancer drug Arimidex (aka anastrozole) is effective in reducing the risk of breast cancer by 53% in postmenopausal women. The finding, based on a trial involving 4,000 women at high risk for the disease is scheduled for presentation next Thursday at the San Antonio Breast Cancer Symposium in Texas.

According to lead author and head of the Cancer Research U.K. Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University Jack Cuzick, "Two other anti-hormone therapies, tamoxifen and raloxifene, are used by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which limit their use. Hopefully, our findings will lead to an alternative prevention therapy with fewer side effects for postmenopausal women at high risk for developing breast cancer.

Breast cancer is the most common form of cancer for women, and it is now estimated that approximately 80% of those suffering from the disease here in the US have tumors with high levels of hormone receptors fueled by the hormone estrogen. Arimidex’s effectiveness lies in the fact that it blocks the body from making estrogen.

Cuzick’s research included more than 4,000 postmenopausal women at increased risk for breast cancer due to having two or more blood relatives with breast cancer, having a mother or sister who developed breast cancer before age 50, or having a mother or sister who had breast cancer in both breasts. About 2,000 of them were given Arimidex for five years while the others took a placebo. In the end, those who took the drug were found to be 53% percent less likely to develop breast cancer than those who took the dummy medication. Side effects for them included hot flashes and small increases in muscle aches and pains.

"This is very exciting information, and it is great to have a less toxic option to offer patients in the preventative arena," stated Dr. Amy Tiersten, associate professor of medicine at the Icahn School of Medicine at Mount Sinai, in Manhattan. “Although tamoxifen and raloxifene can also cut a woman's odds for breast cancer, these medications can slightly increase the risk of blood clots."

Note: It should be pointed out that Cuzick’s study received funding from the drug companies AstraZeneca (maker of Arimidex) and Sanofi-Aventis, and that he is on AstaZeneca’s speaker's bureau.

Advertisement

Life

  • Dead babies found
    Seven dead babies were found in Utah resident Megan Huntsman's old home
    Video
    Shocking Discovery
  • Kendall Jenner
    Get the Coachella looks: Kendall Jenner’s nose ring, green hair and edgy nails
    Camera
    Coachella Look
  • Dog's Easter basket
    How to fill your dog’s Easter basket with the perfect toys
    Easter Basket
  • Rabbit owners
    Bringing home the bunny: Important information for rabbit owners
    Camera
    7 Photos
  • Haunted island
    The world’s most haunted island may soon be the most haunted luxury resort
    Haunted Resort
  • Sunken ferry
    Search continues for missing passengers after a ferry sinks off the South Korean coast
    Video
    Sunken Ferry

User login

Log in
Sign in with your email and password. Or reset your password.
Write for us
Interested in becoming an Examiner and sharing your experience and passion? We're always looking for quality writers. Find out more about Examiner.com and apply today!